CD274 and small cell lung carcinoma: Notably, the addition of anti-programmed cell death-ligand 1 (PD-L1) antibodies, such as atezolizumab or durvalumab, to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) has resulted in significantly longer overall survival (OS) than with chemotherapy alone [6,7].